These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11369451)

  • 1. Direct effects of GnRH agonists in human hormone-sensitive endometrial cells.
    Sica G; Schinzari G; Angelucci C; Lama G; Iacopino F
    Mol Cell Endocrinol; 2001 May; 176(1-2):121-8. PubMed ID: 11369451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN].
    Zhao LJ; Wei LH; Li XP; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):45-9. PubMed ID: 19563062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells.
    Gründker C; Günthert AR; Hellriegel M; Emons G
    Eur J Endocrinol; 2004 Nov; 151(5):619-28. PubMed ID: 15538941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells.
    Sica G; Iacopino F; Robustelli della Cuna G; Marchetti P; Marini L
    J Cancer Res Clin Oncol; 1994; 120(10):605-9. PubMed ID: 7929532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen activates migration potential of endometrial cancer cells through basement membrane.
    Fujimoto J; Hori M; Ichigo S; Morishita S; Tamaya T
    Tumour Biol; 1996; 17(1):48-57. PubMed ID: 7501972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
    Gründker C; Schlotawa L; Viereck V; Eicke N; Horst A; Kairies B; Emons G
    Eur J Endocrinol; 2004 Jul; 151(1):141-9. PubMed ID: 15248835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
    Zhao S; Chen X; Lu X; Yu Y; Feng Y
    Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
    Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
    Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma.
    Lamb CA; Helguero LA; Fabris V; Lucas C; Molinolo AA; Lanari C
    Breast Cancer Res Treat; 2003 May; 79(1):25-35. PubMed ID: 12779079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct antiproliferative effect of triptorelin on human breast cancer cells.
    Marini L; Iacopino F; Schinzari G; Robustelli della Cuna FS; Mantovani G; Sica G
    Anticancer Res; 1994; 14(5A):1881-5. PubMed ID: 7847821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines.
    Sica G; Iacopino F; Marini L; Robustelli della Cuna G
    Clin Ther; 1992; 14 Suppl A():87-96. PubMed ID: 1535023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.
    Emons G; Schröder B; Ortmann O; Westphalen S; Schulz KD; Schally AV
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1458-64. PubMed ID: 8263128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation.
    Gründker C; Günthert AR; Millar RP; Emons G
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1427-30. PubMed ID: 11889221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
    van den Berg HW; Martin J; Lynch M
    Br J Cancer; 1990 Apr; 61(4):504-7. PubMed ID: 2139575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin‑releasing hormone inhibits the proliferation and motility of nasopharyngeal carcinoma cells.
    Teng LH; Ahmad M; Ng WT; Sabaratnam S; Rasan MI; Parhar I; Khoo AS
    Mol Med Rep; 2015 Oct; 12(4):4909-16. PubMed ID: 26151677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression.
    Chegini N; Ma C; Tang XM; Williams RS
    Mol Hum Reprod; 2002 Dec; 8(12):1071-8. PubMed ID: 12468639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.
    Günthert AR; Gründker C; Olota A; Läsche J; Eicke N; Emons G
    Eur J Endocrinol; 2005 Oct; 153(4):613-25. PubMed ID: 16189183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
    Xu Y; Tong J; Ai Z; Wang J; Teng Y
    J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibitory effect of LH-RH analogs on human breast cancer cells.
    Scambia G; Panici PB; Baiocchi G; Perrone L; Gaggini C; Iacobelli S; Mancuso S
    Anticancer Res; 1988; 8(1):187-90. PubMed ID: 2965864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
    Gründker C; Völker P; Schulz KD; Emons G
    Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.